UP
koKRtier 1 1분
[대원제약] 투자판단관련주요경영사항 (미란성 위식도역류질환 환자를 대상으로 DW4421(성분명: 파도프라잔) 투여 후 유효성 및 안전성을 평가하기 위한 제3상 임상시험에 대한 Topline 결과 발표)
No RSS summary is available. Open the original link to read more.
Company
대원제약· 003220
DAEWON PHARMACEUTICAL CO.,LTD
Showing 5 RSS articles and DART filings mapped to this company, sorted by time.
- Market
- LISTED
- Items
- 5
Recent news & filings
UP
koKRtier 1 1분
[대원제약] 기업설명회(IR)개최(안내공시)
No RSS summary is available. Open the original link to read more.
UP
koKRtier 1 1분
[대원제약] 공정거래자율준수프로그램운영현황(안내공시)
No RSS summary is available. Open the original link to read more.
UP
koKRtier 1 1분
[대원제약] 반기보고서 (2026.06)
No RSS summary is available. Open the original link to read more.
UP
koKRtier 1 1분
[DAEWON Pharmaceutical] Corporate Governance Report Disclosureko→en
No RSS summary is available. Open the original link to read more.